

Guidelines for Public and Patient Involvement in Neurotechnology in the United Kingdom

Amparo Güemes Gonzalez^{1*}, Tiago da Silva Costa^{2*}, Tamar Makin^{3*}

¹ *Electrical Engineering Division, Department of Engineering, University of Cambridge, Cambridge, United Kingdom*

² *Northern Centre for Mood Disorders, Newcastle University, Newcastle, United Kingdom*

³ *MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom*

* *Equal contribution*

Corresponding authors: ag2239@cam.ac.uk, tiago.da-silva-costa@newcastle.ac.uk, and tm761@cam.ac.uk

Abstract

Neurotechnologies are increasingly becoming integrated in our everyday lives, our bodies and minds. As the popularity and impact of neurotech grows, so does our responsibility to ensure we understand its particular ethical and societal implications. Enabling end-users and other stakeholders to participate in the development of neurotechnology, even at its earliest stages of conception, will help us better navigate our design around these serious considerations, and deliver more impactful technologies. There are many different terms and frameworks to articulate the concept of involving end users in the technology development lifecycle: 'Public and Patient Involvement and Engagement' (PPIE), 'lived experience', 'co-design', 'co-production'. What is lacking are clear guidelines for implementing a robust PPIE process in neurotechnology. While general advice is available online, it is down to individuals (and their funders) to carve up their own approach to meaningful involvement. Here we present guidance for UK-based researchers and engineers to conduct PPI for neurotechnology. The overall aim is the establishment of gold-standard PPIE methodologies in the neurotechnology space that bring patient and public insights at the forefront of our scientific inquiry and product development.

1. BACKGROUND

1.1. What is PPIE, and how is it relevant for neurotechnologies?

To ensure that research for innovation is successful, there is a need for meaningful involvement of end users in the research and development process, with the aim to improve the quality and impact of research while also emphasizing responsible research practices. PPIE stands for 'Public and Patient Involvement and Engagement' in research (see *UK Standards*[1] and *VOCAL* [2]for introduction guides). This enables researchers, users and stakeholders to work in partnership to guide the decisions made about the development of technology, and how it will be implemented. Here we focus on the active involvement of potential users of **neurotechnologies** and their stakeholders in related research (for an overview, see the *Royal Society iHuman report for neural interfaces*[3]). While the key principles of successful PPIE are broadly suitable for any research, neurotechnologies have some unique user-centred characteristics and ethical considerations that we wish to highlight in our guidelines.

Neurotechnologies can be broadly defined as devices that are specifically designed to interact with the user's nervous system, by recording, extracting or modulating neural activity. This very broad definition includes neurotechnologies which can be applied for very different classes of devices and tools, with varying applications – from entertainment to chronic symptom alleviation. Yes, they raise common and overlapping ethical and societal questions to their intended users. There's a recognised need to build trust and accountability for neurotechnologies, and this can be enabled by better involvement of the relevant stakeholders in the research and development of these novel technologies, as well as broader engagement and information sharing.

While ‘involvement and ‘engagement’ in research might seem like straightforward and overlapping concepts, in the context of PPIE they have more precise meanings. **Involvement** refers to the active engagement of patients, the public and other stakeholders as collaborators in the design and oversight of a research project. The idea is that fully cooked protocols are not just presented to a group of “lay people” for tokenistic criticism but rather that those with lived experience are empowered to act as true partners. This makes research more likely to align to real-world needs and therefore more likely to be impactful. **Engagement** relates to broader societal involvement, to increase transparency of processes, trust in outputs.

Other overlapping frameworks will discuss “PICE” (standing for ‘Public Involvement and Community Engagement’), “co-production”, “co-design” or “lived experience”. For consistency, below we will continue to use the term PPI. However, our guidelines are designed for involving potential neurotechnology users, their communities and carers, and other relevant stakeholders, regardless of their clinical state: we consider patients, other consumers / end users, and the general public. The aim is to establish partnerships with experts by experience.

1.2. Why should I invest in PPI?

Neurotechnologies are projected to increasingly become a part of our everyday lives, and even our bodies and minds. This increased intimacy between humans and technology opens unprecedented new opportunities to improve society – but also potential risks. As neurotechnologies become more popular and their impact grows, so does our responsibility to ensure we understand its implications and the boundaries of humanity we want to preserve. Risks relate therefore to safety and ethical considerations (as detailed in the *iHuman report* [3]). Beyond the traditional user considerations (e.g. costs, accessibility), specific neurotechnological concerns include: autonomy, agency, identity and responsibility for a brain in a neural interface; the use of neurotechnologies for human enhancement to augment human capacity; societal consequences of widespread technological applications; control of neural data and data privacy, and; and other inequalities ensuing non-inclusive design. PPI can help better understand how to navigate neurotechnology design around these serious concerns.

There are also potential benefits for designing and implementing a successful PPI strategy, starting with recruitment of study partners, and ending with dissemination to ensure wider impact and applicability of the findings. PPI could benefit multiple research stages, starting from identifying research opportunities and fundraising and setting up ethical guidelines, to co-design of technology elements, co-development of user-facing information and materials, involvement in synthesis of research findings and dissemination activities. However, a PPI strategy can be challenging to plan and manage (see a good summary in Section 1.2.1 in this *‘How To’ PPIE guide by LBG*[4]). For these reasons, many major UK funders are now requiring that PPI activities are embedded and formally costed in grant applications [Some examples from *EPSRC*[5], *UKRI*[6] and *Wellcome*[7]]. Funding panels increasingly evaluate PPI, and its impact, including it as an assessment criterion when reviewing grants – both the PPI strategy as part of the research proposal, but also evidence that there was end-user involvement in the development of the proposal itself. For example, the EPSRC ‘Research and partnership hubs for health technologies’ 2023 grant call formally requires applications to submit a “PPI and partnership working plan as part of their submission”[8]. As such, a successful track record in setting up a PPI programmes is becoming a valuable qualification for applicants. In principle, the relevant stakeholders can be involved in the earliest stages of the research cycle (e.g., agenda setting, grant writing, research design).

Indeed, there are concrete benefits for enabling PPI as part of the full cycle of innovation, from ideas to adoption. Rather than developing a technology and testing post-hoc whether it met the needs of diverse users, it is more beneficial, efficacious and ethical to start with the identified needs of users

(e.g. in mental health[9]), involve them in the development of a roadmap that also addresses user-centred concerns. Integrating continuous and bidirectional feedback from partners throughout the research process has the potential to enhance the quality, relevance, and ethical foundation of innovative research, and is expected to result in greater impact.

2. GETTING STARTED

We strongly recommend that you pre-register your PPI strategy, including your goals, desired outcome measures, activity, and make up of your PPI prior to conducting the involvement. [Here, we want to have a link for a very simple form on our website, so that people can consider submitting their PPI plans for peer review]. This will improve the transparency of the project, will allow you to seek feedback at the earliest stages of your plan from your peers and the relevant stakeholders, and will help demonstrate your commitment to the relevant communities. It is also advised, whenever possible, to include your PPI partners in the development of your PPI strategy.

2.1. Map out your motivations and general strategy

It is crucial to begin PPI work by considering the motivation for conducting the PPI and constructing a strategy to meet it: define aims and develop the appropriate methods to achieve them. The NIHR has developed a PPI planner for this purpose[10]. Here are some key questions to guide PPI within a project:

- What is the purpose for setting up PPI within the project? You should think about what it is exactly you are hoping to be involved in: Are you looking for involvement with the development of project proposals? Investigate potential users' attitudes toward neurotech research? Test specific features of the technology? Decide on user interfaces? Create rapport for support with dissemination activities? Promotion and dissemination of the project to aid recruitment? Or long-term oversight over project progression?
- Who are the relevant stake-holders? What experiential expertise do you require? Who do you want to involve and how will you reach them? (see Section 2.2)
- Who will be the PPI lead? This role is usually distinct from other essential aspects of PPI organisation/admin/facilitation (see Figure 1). NIHR have details of what this involves[11].
- What type of resources and staff capacity / time will you have available to support your PPI strategy? (See Section 2.4)
- What are some key specific open questions/decisions that you planning have help with? If you are working with patients, NICE has helpful guides on shared decision making for clinicians that could be translatable into this space[12].
- What level(s) of involvement will be appropriate for satisfying the project's aims and feasible within the budget / time available? (e.g., surveys, ad hoc focus groups, consultation workshops, advisory boards, integration in the team as co-researchers). NICE has some examples of potential platforms for this use[13].
- What is your timeline? How often will you need input from your target PPI partners? Here is an example of a schedule of PPI activities developed by Cambridge BRC[14].
- What would be the potential benefits of/to the stakeholders taking part in the PPI? How might you support the development of your PPI partners?
- Where in your plan could you allow for flexibility? For example, will people need to travel, or can they be involved remotely?
- Who could help you in delivering your plan? (e.g. institutional support, charities, funders, user groups). For example, if looking to set-up a focus group you might find that patient groups already have well established forums that you could be invited to.
- How will you advertise the PPI opportunities inclusively in practical terms?

- How will you access funding to pay people for their time, and help support their involvement, e.g. travel or carer costs? Guidance on payments for PPI is available, for example, from NIHR[15], including a cost calculator[16], and Health Data Research UK[17].
- What additional resources (time, cost, expertise) will you need to meet your various engagement levels? The National Co-ordinating Centre for Public Engagement has a helpful list of funding opportunities available to specifically support health and life sciences PPI activities, many of relevance to neurotech[18].
- How will you track PPI work to remain accountable to plans, ensuring PPI work doesn't become tokenistic? How will you use this to measure the impact of PPI on the project?

2.2. Map out your relevant stakeholders: Who should I involve in the PPI plan?

When developing a neurotechnology, it can be challenging to know who the research needs to engage with. While patients are often associated with PPI, with the unique considerations of neurotechnologies you might need to think more intersectional. For a panoramic view of how your technology will fit with the abilities, needs and beliefs of your users, your PPI should reflect the full range of potential stakeholders, and not just your primary user group.

Start by defining your target group(s). This should include not only your target user or clinical community, but any other member of society that could be impacted by your technology, both in the immediate and the long term. For example, those caring for the users you hope to target primarily. You might benefit from the insight of users of more mature neurotechnologies that may share some common ethical and/or practical considerations as yourself. Early reciprocal relationships with disease-specific medical charities can provide essential resources, information, and connections to relevant




Figure 1. Roles in PPI decision-making activities. Identified groups work together to ensure meaningful involvement and engagement of patients, public, carers, and stakeholders throughout the research process. The PPI lead serves as the principal investigator and oversees the PPI strategy. The PPI 'User/Patient/Carer/Public' co-investigators work alongside the lead, mentored by them. The PPI Co-ordinator is a staff member in the team who holds the PPI relationships with stakeholders and organizes PPI activities. They work closely with all other team members. The Stakeholder Advisory Group consists of 10-12 anchor public members who provide long-term engagement and expertise throughout the duration of the study. Co-researchers participate in specific elements of the study, such as usability testing workshops, supporting participant recruitment, or conducting user-experience qualitative work. Stakeholders from the community are invited to consultation meetings and form a network of engaged stakeholders, contributing with their perspectives and insights to the study.

stakeholders, making it an efficient initial step in identifying key partners. It is also important to consider different relevant demographics, as people from different backgrounds, particularly population groups who are often underserved by research, might afford a different attitude to neurotechnologies. It is often also worth approaching those who seem more likely to object/reject the technology, as they might offer a valid and constructive viewpoint to draw from. A diagram illustrating the different roles identified in the decision-making process of PPI activities is shown in Figure 1.

Here are some general guidelines for helping you identify the desired PPI partners:

- Who are the direct users/beneficiaries of the neurotechnology that you are developing? There are available tools to help you identify populations affected by a particular condition[19]. For example, the Charities Research Involvement Group offers a directory[20].
- Who are the specific population groups who will be involved, and in particular those who's affiliation might influence their attitude towards your technology (e.g. religion or cultural preferences).
- Who are the indirect beneficiaries (e.g. care-givers, NHS professionals, employers) of successful implementation of the technology?
- What other potential user groups would be impacted from the technology in the long-term, if it is successful?
- Who will be choosing/administering the technology? Who will be paying for it? Who will commission its use in clinical groups or more widespread use? Is it all paid up-front or are there ongoing costs? Is it to be used forever? When will it need replacing?
- Who is likely to object to the implementation of your neurotechnology?
- Who is likely to be displaced / deprecated if your neurotechnology becomes a success? Will some aspects of the service they provided be missed?
- Are there any relevant technologies that are more mature in terms of societal penetration?

2.2.1. How to recruit diversity of partners required and reach the hard-to-reach?

You will need to develop a strategy to ensure that your relationship with PPI partners is inclusive, diverse and representative of the populations you want to work with. If groups are under-represented in the initial stages of technological development, then the technology might not meet their needs. There are multiple challenges. You need to proactively and reciprocally engage with a broad range of views within the relevant population and ensure they are appropriately supported to facilitate their involvement. As PPI is about the inclusion of individual experiences, individuals in groups will have different interests in why they are getting involved and what they are hoping to get out of it. Focusing on people with a specific demand will help you understand the perceived needs and hopes for neurotech development in that particular area.

Like all aspects of the project, the involvement strategy may have limitations, and therefore it is encouraged to maintain a continuous evaluation and adaptation strategy. Balancing these needs will require cultural sensitivity and the engagement of a whole community, crucial for building trust. To build and maintain this trust, you must always be honest about your aims and never condescend your partners. For example, if you are not really offering to build a patient led study or a co-produced study, say so and also be clear about what you need help with.

To ensure that you reach the relevant partners and inclusivity, it is crucial to consider:

- Diversity in your target group. This may include age, gender, physical, education level, cognitive ability, race, lifestyle, religious beliefs, cultural, financial ability, societal preferences, and technological affinity. The bottom line is that there is no "general public" and you need to define the characteristics of the people that have the relevant experience for project development,

while bearing in mind the target group characteristics. Also acknowledge the PPI process in itself might lead to a redefinition of the target population.

- Leveraging national structures and building reciprocal, long-term relationships with community-based organizations, both of patients and non-patients. These can be very important ways to reach some key population members (group leaders / gatekeepers / social hubs) for “snowball” recruitment. At the same time, make sure to include multiple perspectives/organisations as your partners.
 - There are national structures that can help you identify partners. This includes many NIHR initiatives, such as the INCLUDE project[21], the Equality Impact Assessment (EqIA) Toolkit[22], the Health Determinants Research Collaborations[23] and the Research Support Service[24], which can give you specific guidance on the design and costing of your PPI. There are also community organisations such as Haref’s Connected Voice[25] and NHS England’s Voluntary, Community and Social Enterprise (VCSE) Health and Wellbeing Alliance[26].
 - Thinking more locally, NHS Trust and Universities will also have PPI teams, that have already developed relationships with the local communities. NIHR also runs the Applied Research Collaborations (ARCs)[27], which funds local collaborations and research deployment, particularly if they are directly addressing patient benefit. Understanding and reaching out to the local infrastructures is worthwhile, as it can save you a lot of time and effort down the road.
 - For patients, groups tend to be better embedded in national PPI pathways. They can be advocacy groups, charities, or patient groups at specialist national clinics. Specialist nurses at NHS clinics will be great points of contact to understand which groups are important for patients and carers (some will be virtual, such as groups on Facebook).
 - For non-patients, these can be members of “do-it-yourself” communities, using readily available components, commercial products, or ad-hoc adaptations beyond the marketed intent. It might be worth searching for online discussion forums, such as those for “internet of things” builders.
 - It is also worth considering if there are opinion makers, such as columnists, bloggers or social media influencers already talking about your technology. These might be important people to reach out to.
- Shared language that is accessible. You need to tailor your communication, starting with avoiding technical jargon. You might need different materials for different stakeholder groups, and even consider the need to translate it to different languages. Make sure you use trusted services, as data privacy will be a concern – ‘the big word’ is an example of service provider in this area[28].
- When you reach out to individuals or groups, be clear in your aims for the PPI, as well as desired roles and expectation for the various parties involved. There may be stages in the research cycle where PPI work may have less impact / restrictions that limit how much can be changed. It is therefore important that you are open and honest in your communication on the potential and actual impact of the PPI activities at various steps of the way.
- Accessibility in physical and digital environments and logistics. Some people might be reluctant or unable to meet online, use certain digital platforms or meet in groups in person, at least until there is shared trust. Be flexible but also honest about what you can offer.
- Incentives and benefits. The time people spend in PPI activities should not be taken for granted. This is also particularly important if you want to reach those that incur a cost during involvement (e.g. time off work, child care, travel expenses). It is also important to recognise that different people have different motivations when engaging in PPI activities, and some will not ask for payment, some are not able to receive payment – medically retired, or benefit status. You will need to consider alternative ways of recognising the contributions, for example you can provide education / training / or (access to) digital technologies.
- You can also try to widen participation to encourage people to reach out to you and volunteer to contribute to the PPI. There are organised hubs for doing this, for example with NIHR[29],

VOICE[30] and Shaping our Lives[31]. You could also contact organisations / groups that work in the area and asking them to share your call for PPI on their social media accounts.

2.3. Set out a clear outcome for your PPI strategy: how will I measure the success of my PPI strategy?

The PPI is meant to improve the quality of research and successful adoption of the neurotechnology. To build evidence on the impact of the PPI activities, justify the allocation of resources, and better plan for future projects, PPI should be formally reviewed.

Now that you have set out your general motivation and key stakeholders, the next step is to clearly outline the desired outcomes and methods to get there. This could be achieved, for example, by identifying what are some potential considerations that might impact users attitudes towards the technology (e.g. astatic, practical, societal, privacy and data security). Here again, it is important to consider the unique concerns that neurotechnologies introduces, including questions concerning autonomy, agency, identity and responsibility for a brain in a neural interface; societal consequences of widespread technological applications; control of neural data and data privacy, and access to technology and other inequalities ensuing non-inclusive design.

Make sure the objectives are specific, measurable, achievable, relevant, and time-bound (SMART). As much as possible, we recommend using standardised measures.

With regards to **PPI metrics**, here are some standards of good practice:

- Document all PPI activities, so you can report on them and identify specifically what value each opportunity brought. Some guidance documents will call this an “impact log”[32].
- Design qualitative feedback surveys and questionnaires to identify points of consensus and diversity in values and preferences associated with the PPI by all those involved in the project.
- Ask people to reflect and provide feedback during semi-structured interviews of representatives with relevant lived experience about their perspective and recommendations for the neurotechnology under development.
- Feedback forms for individuals involved in the PPI to record values and preferences.
- Metrics with descriptive statistics of PPI participants key demographics that help to evaluate the diversity aims, as stated in the previous section.
- White-papers, consensus reports or recommendation reviews, co-authored by the PPI stakeholders or including contributions from the PPI group.
- Successful funding or publications facilitated directly by the PPI strategy and team work.
- Sharing your PPI materials and outcomes with other relevant parties.
- If the aim was to co-produce the study, then assess how power was effectively shared.
- There is also value in subjective measures, e.g. by reflective processes. This could help you identify how the people involved found the experience, and whether they experienced any benefits from the engagement.

With regards to the **PPI impact** on the overall project outcomes, it is important to be specific about what benefits and changes it brought to your project, particularly when reporting to grant panels. Also consider the need to offer feedback to those that participated in your PPI activities. NIHR has guidance on this[33]. A clear the goal should be set out in advance for your PPI activity against which the success of the PPI can be evaluated. This could involve:

- Ways in which PPI helped identify new values to influence the research and development strategy, e.g. incorporating user testing at an earlier phase of the process. Did it change the research priority?

- Improve the potential feasibility of your technology, e.g. by raising real world practical considerations that might have been overlooked by the research team? Did it change the design in any way?
- Contribute to broadening the inclusivity of the neurotechnology, e.g. by addressing new diversity considerations by the team.
- Help change people’s attitudes towards the neurotechnology, e.g. by convincing a grant panel that the technology will be well received by the intended users.
- Improved the resources of the research project, e.g. by increasing the diversity of the participants pool.
- Change the way personal data is being managed, e.g. by creating new choices to users on how their data should be shared, stored or protected. This should include consideration of the mechanisms for “option out” of the sharing of neural data, and what this means in the context of the proposed project.
- Identify new factors that might enable or inhibit the research strategy, e.g. by realising diverging preferences by different user groups.
- Benefit the involved individuals, e.g. by building trust around the use of neurotechnology.
- Contribute to the confidence and the ability of the researchers to conduct successful PPI.

If you are interested in a specific framework to assess PPI, you can have a look at our resources page.

2.4. What resources will I need?

There are a lot of shared resources to draw from, you don’t have to reinvent the wheel. Consider the aims of your planned activity - Are you looking to canvas a broad range of perspectives, or would you prefer to engage a small group of users more extensively? Is it a face-to-face activity or virtual? Are you looking for an interactive exchange, or a survey? A workshop with multiple stakeholders, or one-on-one interviews? Do you have geographical restrictions? There are pros and cons for each approach, and it is likely that, depending on your budget, you will seek for a combination of approaches.

Meaningful involvement requires quite a bit of resources, especially if you are building a long-term activity [34]. First and foremost, successful PPI aims to create trusted, reciprocal relationships built on reliable and regular communication, and there is often a need to appoint personnel for this purpose. The administrative load might also peak at various points (e.g. when involving stakeholders, organising events and when disseminating engagement outcomes). When applying for funding, you will need to recognise and value people’s time and related involvement expenses, and a monetary honorarium is often expected. Many PPI experts recommend embedding training for both researchers and the stakeholders, particularly if those are involved in key roles (see opportunities provided by Imperial College London[35] and the NIHR[36]). Either way, you will want to build in sufficient time and resources for individuals to familiarise themselves with the project. When determining the timeline of the desired programme, it is important to consider the feasibility for the contributions of those involved, including possible prior commitments and daily constraints, but also potential deteriorating health and unexpected delays.

It is generally agreed that when documenting participant’s preferences and opinions, ethics approval does not need to be sought[37]. However, the boundaries between research and involvement can get blurry, and we recommend that you discuss your planned PPI activities with your local ethics committee. Even if you will not need to apply for ethics approval, you will still be expected to follow GDPR guidelines when handling personal and identifiable information of the PPI participants [38].

3. How to improve transparency and accountability? Recommended practices check list

Engage and communicate: remember PPI involves bidirectional input, where active listening, responsiveness, and mutual understanding are key to developing effective and patient-centred neurotechnology solutions.

- **Long-term engagement** is particularly important in neurotechnology because the research often extends over extended periods. Plan for sustained PPI activities and encourage long-term bidirectional commitment and retention of PPI representatives throughout the lifecycle of a study or project, which is crucial to maintain continuity, relevance, and impact. Sometimes it may be challenging to implement long-term involvement due to restrictions associated to the grant-related nature of the funding for PPI. In this case, you could consider providing community groups or patient advocates with access to university facilities, or offer them training and capacity-building programs that empower them to take on more active roles in the research process, contributing their skills and expertise.
- Involve relevant people from the earliest possible stage in the research process, ideally from shaping the initial research question and PPI strategy.
- Equally plan and budget for additional involvement throughout the study: there is huge value to bringing in fresh eyes throughout the research process thus inviting new stakeholders into the process at key stages can work well.
- Onboard and induct your PPI strategy from the beginning: explain your goals, your action plan, timeline and gaps, so PPI partners have clear expectations and understand their role.
- Discuss opportunities to continue partnership in later stages of research, like PPI evaluation and dissemination activities.
- Conduct community outreach programs, like educational sessions, workshops, virtual reality demonstrations and webinars, to raise awareness about neurotechnology, its potential benefits, and opportunities for involvement in research and development. Be mindful of the costs of these activities and digital skills, our goal is to make it accessible and inclusive to all.
- Collaborate with identified stakeholders to create patient/user journey maps, identifying pain points and unmet needs, which can guide the development of targeted neurotechnology solutions.
- Partner with existing PPI infrastructures and advocacy groups focused on neurological conditions or neurotechnologies to facilitate communication and connections with the relevant community.
- Allow individuals to physically interact with early-stage neurotechnology prototypes, enabling them to provide feedback on comfort, fit, and usability. Be open to adjusting design elements based on this feedback.
- Offer plain language summaries, infographics, and video content to enhance understanding of complex neurotechnological concepts.

Acknowledge the contributions of partners and stakeholders:

- Explicitly acknowledge the unique experiences and insights of the target users, relatives and caregivers in the development of neurotechnological solutions.
- Ensure that their contributions are highlighted and integrated into the development process. For example, provide regular updates on how their insights have directly impacted the design and functionalities of the neurotechnology being developed.
- Consolidate feedback based on success measures and report it back to PPI partners. This can also guide them to tailor their support.
- Present insights in a clear and accessible manner, demonstrating how their participation informed decision-making throughout the development process.

Trust and Transparency:

- Build trust by involving individuals with relevant lived experience in supporting the design and oversighting of the study from its earliest stages, and demonstrate a commitment to incorporating their feedback and concerns.
- Clearly document the neurotechnology development process, including the role of the PPI partners and public input at various stages, in publicly accessible reports and websites.
- Be clear on your strategy for an ethical use of neurotechnologies and this in your PPI strategy. PP partners should also have a say in shaping guidelines regarding the ethical use of these technologies.
- Involve PPI representatives in identifying, understanding, and mitigating risks associated with neurotechnologies, including physical, psychological, or privacy-related and ensure transparency on them.
- Publicly share decisions related to the design, development, and delivery of neurotechnological solutions, clearly explaining the reasoning behind each decision.
- Provide a platform for stakeholders to voice concerns about any decisions that may impact the neurotechnology's accessibility or usability.
- Engage in transparent discussions regarding intellectual property rights, especially concerning neurotechnology advancements and potential barriers to accessibility.
- Address concerns about the influence of IP rights on pricing, availability, and equitable access to neurotechnological solutions.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the following people for their contributions to reviewing and improving this guidelines: Neil Roberts (manager director at SEHTA), Chris Gibbs (Research Involvement Coordinator, St Nicholas Hospital), Rebecca Woodcock (Patient and Public Involvement Manager: Mental Health & Technology Research, NIHR MindTech MedTech Co-operative), Vanessa Pinfold (Research Director and Co-Founder, McPin), Annabel Walsh (Public Involvement in Research Manager , McPin), Sian Robinson (Prof of Lifecourse & Lifestyle, Newcastle University). AGG acknowledges funding support from the Royal Commission for the Exhibition of 1851 and L'Oréal-UNESCO UK and Ireland For Women in Science Rising Talent Programme. TC is supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC4 Award). TRM was funded by the Wellcome Trust (215575/Z/19/Z) and the Medical Research Council (MC_UU_00030/10)

REFERENCES

- [1] "UK Standards for Public Involvement." Accessed: Mar. 25, 2024. [Online]. Available: <https://sites.google.com/nih.ac.uk/pi-standards/home>
- [2] M. R. C. VOCAL, "Looking forward: Working with the Medical Research Council towards a public involvement strategy," 2022.
- [3] The Royal Society, "iHuman Blurring lines between mind and machine," 2019. Accessed: Mar. 25, 2024. [Online]. Available: <https://royalsociety.org/-/media/policy/projects/ihuman/report-neural-interfaces.pdf>
- [4] "patient and public involvement and engagement in research - a 'how to' guide for researchers." Accessed: Mar. 25, 2024. [Online]. Available: <https://zenodo.org/records/3515811>
- [5] "EPSRC health technologies strategy – UKRI." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.ukri.org/publications/epsrc-health-technologies-strategy/epsrc-health-technologies-strategy/#section-enablers>

- [6] "Public engagement – UKRI." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.ukri.org/what-we-do/public-engagement/>
- [7] "Grant funding schemes and guidance | Grant funding | Wellcome." Accessed: Mar. 25, 2024. [Online]. Available: <https://wellcome.org/grant-funding>
- [8] "Research and partnership hubs for health technologies: full stage – UKRI." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.ukri.org/opportunity/research-and-partnership-hubs-for-health-technologies/>
- [9] World Economic Forum, "Empowering 8 Billion Minds Enabling Better Mental Health for All via the Ethical Adoption of Technologies," 2019. Accessed: Mar. 25, 2024. [Online]. Available: www.weforum.org
- [10] "PPIE Planner." Accessed: Mar. 25, 2024. [Online]. Available: <https://plan4ppie.com/>
- [11] "Definition and role of the designated PPI (Patient and Public Involvement) lead in a research team | NIHR." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nihr.ac.uk/documents/definition-and-role-of-the-designated-ppi-patient-and-public-involvement-lead-in-a-research-team/23441>
- [12] "Overview | Shared decision making | Guidance | NICE." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nice.org.uk/guidance/ng197>
- [13] "Public Involvement Programme | Public involvement - putting you at the heart of our work | NICE and the public | NICE Communities | About | NICE." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nice.org.uk/about/nice-communities/nice-and-the-public/public-involvement/public-involvement-programme>
- [14] "Schedule of Activities 2022-2027 - Cambridge Biomedical Research Centre." Accessed: Mar. 25, 2024. [Online]. Available: <https://cambridgebrc.nihr.ac.uk/public/patient-and-public-involvement-engagement-and-participation-ppi-strategy-2022-2027/ppie-strategy-2022-2027/>
- [15] "NIHR public contributor payment policy | NIHR." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nihr.ac.uk/documents/nihr-public-contributor-payment-policy/31626>
- [16] "Involvement Cost Calculator | INVOLVE." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.invo.org.uk/resource-centre/payment-and-recognition-for-public-involvement/involvement-cost-calculator/>
- [17] Health Data Research UK, "Honoraria and Expenses Policy-Patient and Public Involvement and Engagement Activities," 2023.
- [18] "Funding Opportunities | NCCPE." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.publicengagement.ac.uk/funding-opportunities>
- [19] "Health Equity Assessment Tool (HEAT): executive summary - GOV.UK." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.gov.uk/government/publications/health-equity-assessment-tool-heat/health-equity-assessment-tool-heat-executive-summary>
- [20] "Shared Learning Group on Involvement – Encouraging shared learning about service user and carer involvement between voluntary sector organisations working in the UK." Accessed: Mar. 25, 2024. [Online]. Available: <https://slginvolvement.org.uk/#members>
- [21] M. D. Witham *et al.*, "Developing a roadmap to improve trial delivery for under-served groups: Results from a UK multi-stakeholder process," BioMed Central, Aug. 2020. doi: 10.1186/S13063-020-04613-7.
- [22] "Equality Impact Assessment (EqIA) Toolkit | arc-em.nihr.ac.uk." Accessed: Mar. 25, 2024. [Online]. Available: <https://arc-em.nihr.ac.uk/clahracs-store/equality-impact-assessment-eqia-toolkit>
- [23] "Health Determinants Research Collaborations | NIHR." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nihr.ac.uk/explore-nihr/support/health-determinants-research-collaborations.htm>
- [24] "Research Support Service | NIHR." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nihr.ac.uk/explore-nihr/support/research-support-service/>

- [25] "Haref | Connected Voice." Accessed: Mar. 25, 2024. [Online]. Available: <https://connectedvoice.org.uk/services/haref>
- [26] "NHS England » Voluntary, Community and Social Enterprise (VCSE) Health and Wellbeing Alliance." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.england.nhs.uk/hwalliance/>
- [27] "Collaborating in applied health research | NIHR." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.nihr.ac.uk/explore-nihr/support/collaborating-in-applied-health-research.htm>
- [28] "thebigword." Accessed: Mar. 25, 2024. [Online]. Available: <https://en-gb.thebigword.com/>
- [29] "Home - People in Research." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.peopleinresearch.org/>
- [30] "Voice: Voice Global." Accessed: Mar. 25, 2024. [Online]. Available: <https://voice-global.org/>
- [31] "Need help with user involvement? - Shaping Our Lives." Accessed: Mar. 25, 2024. [Online]. Available: <https://shapingourlives.org.uk/help-with-involvement/>
- [32] "Patient and public involvement impact log – NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol." Accessed: Mar. 25, 2024. [Online]. Available: <https://hprubse.nihr.ac.uk/public-involvement/patient-and-public-involvement-impact-log/>
- [33] Centre for Research in Public Health and Community Care, "Guidance for Researchers: Feedback PATIENT and PUBLIC INVOLVEMENT (PPI): Feedback from Researchers to PPI Contributors," 2018.
- [34] Boehringer Ingelheim and partners, "How to involve and engage patients in digital health tech innovation An Evidence Based Guide," 2023. Accessed: Mar. 25, 2024. [Online]. Available: <https://www.boehringer-ingelheim.com/uk/bipdf/ppie-guide>
- [35] "Public Involvement Training | Faculty of Medicine | Imperial College London." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.imperial.ac.uk/patient-experience-research-centre/ppi/ppi-training/>
- [36] "A course for reviewers of health and social care research." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.learningforinvolvement.org.uk/an-interactive-course-for-new-and-experienced-patient-public-reviewers-of-health-and-social-care-research/>
- [37] "Do I need ethical approval to run an involvement activity? — NIHR School for Primary Care Research." Accessed: Mar. 25, 2024. [Online]. Available: <https://www.spcr.nihr.ac.uk/PPI/resources-for-researchers/faq/do-i-need-ethical-approval-to-run-an-involvement-activity>
- [38] Information Commissioner's Office, "Guide to the General Data Protection Regulation (GDPR)," 2018.